A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia
NCT ID: NCT01678924
Last Updated: 2020-01-07
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
280 participants
INTERVENTIONAL
2013-01-31
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
NCT00612105
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia
NCT01270828
A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia
NCT00599638
A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
NCT00394901
Development of a Bedside Pain Assessment Kit for Postherpetic Neuralgia
NCT01166295
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AGN-214868 Dose 1
AGN-214868 Dose 1 given as injections into the area of pain on Day 1.
AGN-214868
AGN-214868 given as injections into the area of pain on Day 1.
AGN-214868 Dose 2
AGN-214868 Dose 2 given as injections into the area of pain on Day 1.
AGN-214868
AGN-214868 given as injections into the area of pain on Day 1.
AGN-214868 Placebo (Vehicle)
AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
AGN-214868 Placebo (Vehicle)
AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
AGN-214868 Dose 3
AGN-214868 Dose 3 given as injections into the area of pain on Day 1.
AGN-214868
AGN-214868 given as injections into the area of pain on Day 1.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AGN-214868
AGN-214868 given as injections into the area of pain on Day 1.
AGN-214868 Placebo (Vehicle)
AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Anticipated treatment for postherpetic neuralgia during the first 3 months of the study, including oral and topical medications, acupuncture, spinal cord stimulation, transcutaneous nerve stimulation (TNS), or trigger point injection
* Anticipated treatment with pain medication for the treatment of postherpetic neuralgia during the first 3 months of the study
* Use of capsaicin treatment for postherpetic neuralgia within 6 months, or anticipated use during the first 3 months of the study
* Use of botulinum toxin of any serotype for any reason within 6 months, or anticipated use during the study
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Agave Clinical Research, LLC
Mesa, Arizona, United States
Territory Neurology & Research Institute
Tucson, Arizona, United States
Neuro-Pain Medical Center
Fresno, California, United States
University of California, Irvine
Irvine, California, United States
Loma Linda University
Loma Linda, California, United States
Northern California Research Corp
Sacramento, California, United States
Neurological Research Institute
Santa Monica, California, United States
Alpine Clinical Research Center
Boulder, Colorado, United States
The Mile High Research Center
Denver, Colorado, United States
Riverside Clinical Research
Edgewater, Florida, United States
Compass Research, LLC
Orlando, Florida, United States
Drug Studies America
Marietta, Georgia, United States
Injury Care Research, LLC
Boise, Idaho, United States
Millennium Pain Center
Bloomington, Illinois, United States
Beacon Clinical Research
Brockton, Massachusetts, United States
Springfield Neurology Associates, LLC
Springfield, Massachusetts, United States
Michigan Head Pain and Neurology Institute
Ann Arbor, Michigan, United States
Quest Research Institute
Farmington Hills, Michigan, United States
Center for Pharmaceutical Research
Kansas City, Missouri, United States
Clinvest Headache Care Center
Springfield, Missouri, United States
Albuquerque Neuroscience, Inc.
Albuquerque, New Mexico, United States
The Medical Research Network, LLC
New York, New York, United States
Island Neurological Associates, P.C.
Plainview, New York, United States
Wake Research Associates
Raleigh, North Carolina, United States
Plains Medical Clinic
Fargo, North Dakota, United States
COR Clinical Research, LLC
Oklahoma City, Oklahoma, United States
Allegheny Pain Management
Altoona, Pennsylvania, United States
Omega Medical Research
Warwick, Rhode Island, United States
Clinical Trials of South Carolina, LLC
Charleston, South Carolina, United States
PharmaCorp Clinical Trials, Inc
Charleston, South Carolina, United States
Clinical Research of Charleston
Mt. Pleasant, South Carolina, United States
Center for Clinical Studies
Webster, Texas, United States
MultiCare Neuroscience Center of Washington
Tacoma, Washington, United States
AKH Wien
Vienna, , Austria
Wilhelminenspital der Stadt Wien
Vienna, , Austria
SMZ-Ost Donauspital
Vienna, , Austria
Pro scientia med im MARE Klinikum
Kiel, Schleswig-Holstein, Germany
Berlin Research Centre
Berlin, , Germany
Regionales Schmerzzentrum DGS
Bielefeld, , Germany
Bochum Research Centre
Bochum, , Germany
Das Schmerzzentrum Celle
Celle, , Germany
Ambulant study centre
Cologne, , Germany
Leiter des Universitats Schmerz Centrums (USC)
Dresden, , Germany
Neuro-Consil GmbH
Düsseldorf, , Germany
Frankfurt Research Centre
Frankfurt, , Germany
Schmerz und Palliativzentrum Fulda
Fulda, , Germany
Schmerz und Palliativ- Zentrum Goeppingen
Göppingen, , Germany
Klinikum Hanau GmbH
Hanau, , Germany
Neurologische Praxis Heidenheim
Heidenheim, , Germany
Facharzt fur Neurologie
Hoppegarten, , Germany
Schmerzklinik Kiel
Kiel, , Germany
Medamed GmbH
Leipzig, , Germany
Leipzig Research Centre
Leipzig, , Germany
Magdeburg Research Centre
Magdeburg, , Germany
Regionales Schmerz- und Palliativ Zentrum DGS Mainz
Mainz, , Germany
Universitätsklinik Ulm
Ulm, , Germany
Schmerztherapiezentrum Villingen-Schwenningen
Villingen-Schwenningen, , Germany
Poznański Ośrodek Medyczny NOVAMED
Poznan, Poznañ, Poland
Medica Pro Familia Sp. Z.o.o SKA
Gdynia, , Poland
Medica Pro Familia Sp. Z.o.o SKA
Katowice, , Poland
Malopolskie Centrum Medyczne S.C.
Krakow, , Poland
Specjalistyczny Gabinet Neurologiczny
Krakow, , Poland
Nzoz Neuromed
Lublin, , Poland
NZOZ Neuro-Kard
Poznan, , Poland
Osrodek Badan Klinicznych Euromedis Sp. z o.o.
Szczecin, , Poland
Niepubliczny Zaklad Opieki Zdrowotnej
Świdnik, , Poland
Przychodnia Specjalistyczna PROSEN
Warsaw, , Poland
Medica Pro Familia Warszawa
Warsaw, , Poland
Synexus SCM sp. z o.o.
Wroclaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-002240-24
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
214868-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.